Drug Profile
Aminocandin
Alternative Names: HMR-3270; IP960; NXL 201Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aventis
- Class Antifungals
- Mechanism of Action Glucan synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Mycoses in France (Parenteral, Injection)
- 13 Sep 2007 Preclinical trials in Mycoses in France (Parenteral)
- 12 Dec 2006 Aminocandin out-licensed to Novexel worldwide